Advanced search
Publication Cover
Expert Review of Molecular Diagnostics Volume 17, 2017 - Issue 1
Submit an article Journal homepage
3,077
Views
5
CrossRef citations to date
0
Altmetric
Editorial

Molecular diagnosis of tuberculosis: we need solutions that span the healthcare value chain

Emily MacLeanDepartment of Epidemiology & Biostatistics, McGill University, Montreal, Canada;McGill International TB Centre, McGill University, Montreal, CanadaView further author information
,
Sophie HuddartDepartment of Epidemiology & Biostatistics, McGill University, Montreal, Canada;McGill International TB Centre, McGill University, Montreal, CanadaView further author information
&
Madhukar PaiDepartment of Epidemiology & Biostatistics, McGill University, Montreal, Canada;McGill International TB Centre, McGill University, Montreal, CanadaCorrespondence[email protected]
View further author information
Pages 5-7 | Received 11 Oct 2016, Accepted 24 Nov 2016, Published online: 05 Dec 2016

References

  • World Health Organization. Global tuberculosis report 2016. Geneva: WHO; 2016.
  • Kik SV, Denkinger CM, Chedore P, et al. Replacing smear microscopy for the diagnosis of tuberculosis: what is the market potential? Eur Respir J. 2014;43(6):1793–1796. PubMed PMID: 24525440. DOI:10.1183/09031936.00217313
  • World Health Organization. Policy statement. Molecular line probe assays for rapid screening of patients at risk of multidrug-resistant tuberculosis (MDR-TB). Geneva: World Health Organization; 2008 [cited 2008]. Available from: http://www.who.int/tb/dots/laboratory/policy/en/index4.html; http://www.who.int/tb/features_archive/policy_statement.pdf
  • World Health Organization. Policy update: automated real-time nucleic acid amplification technology for rapid and simultaneous detection of tuberculosis and rifampicin resistance: Xpert MTB/RIF system for the diagnosis of pulmonary and extrapulmonary TB in adults and children. 2013. [cited 2016 Nov 13]. Available from: http://www.stoptb.org/wg/gli/assets/documents/WHO%20Policy%20Statement%20on%20Xpert%20MTB-RIF%202013%20pre%20publication%2022102013.pdf
  • Albert H, Nathavitharana R, Isaacs C, et al. Development, roll-out, and impact of Xpert MTB/RIF for tuberculosis: what lessons have we learnt, and how can we do better? Eur Resp Journal. 2016;48:516–525.
  • Theron G, Zijenah L, Chanda D, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2013;383:424–435. PubMed PMID: 24176144. DOI:10.1016/S0140-6736(13)62073-5
  • Churchyard GJ, Stevens WS, Mametja LD, et al. Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. Lancet Glob Health. 2015;3(8):e450–e457. PubMed PMID: 26187490. DOI:10.1016/S2214-109X(15)00100-X
  • Puri L, Oghor C, Denkinger CM, et al. Xpert MTB/RIF for tuberculosis testing: access and price in highly privatised health markets. Lancet Glob Health. 2016;4(2):e94–e95. PubMed PMID: 26823226. DOI:10.1016/S2214-109X(15)00269-7
  • Kik SV, Denkinger CM, Casenghi M, et al. Tuberculosis diagnostics: which target product profiles should be prioritised? Eur Respir J. 2014;44(2):537–540. PubMed PMID: 24696110 DOI:10.1183/09031936.00027714
  • World Health Organization. The use of loop-mediated isothermal amplification (TB-LAMP) for the diagnosis of pulmonary tuberculosis: policy guidance. Geneva: WHO; 2016. Available from: http://apps.who.int/iris/bitstream/10665/249154/1/9789241511186-eng.pdf?ua=1
  • Denkinger CM, Kik SV, Pai M. Robust, reliable and resilient: designing molecular tuberculosis tests for microscopy centers in developing countries. Expert Rev Mol Diagn. 2013;13(8):763–767. PubMed PMID: 24151844. DOI:10.1586/14737159.2013.850034
  • Denkinger CM, Nicolau I, Ramsay A, et al. Are peripheral microscopy centres ready for next generation molecular tuberculosis diagnostics? Eur Respir J. 2013;42(2):544–547. PubMed PMID: 23904551. DOI:10.1183/09031936.00081113
  • World Health Organization. The use of molecular line probe assays for the detection of resistance to second-line anti-tuberculosis drugs. Policy guidance. Geneva: WHO; 2016. Available from: http://www.who.int/entity/tb/areas-of-work/laboratory/WHOPolicyStatementSLLPA.pdf?ua=1
  • World Health Organization. The shorter MDR-TB regimen. Geneva: WHO; 2016. Available from: http://www.who.int/tb/Short_MDR_regimen_factsheet.pdf
  • Huddart S, MacLean E, Pai M. Location, location, location: where are tuberculosis diagnostic and treatment services available in highest burden countries? Lancet Global Health. 2016;4:e907-e908.
  • Pai M, Behr M, Dowdy D, et al. Tuberculosis. Nature Rev Dis Primers. 2016;2:1–23.
  • Pai M, Schito M. Tuberculosis diagnostics in 2015: landscape, priorities, needs, and prospects. J Infect Dis. 2015;211(S2):S21–S28.
  • Wells WA, Boehme CC, Cobelens FG, et al. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis. 2013;13(5):449–458. PubMed PMID: 23531393. DOI:10.1016/S1473-3099(13)70025-2
  • Pankhurst LJ, Del Ojo Elias C, Votintseva AA, et al. Rapid, comprehensive, and affordable mycobacterial diagnosis with whole-genome sequencing: a prospective study. Lancet Respir Med. 2016;4(1):49–58. PubMed PMID: 26669893; PubMed Central PMCID: PMCPMC4698465. DOI:10.1016/S2213-2600(15)00466-X
  • Andre E, Isaacs C, Affolabi D, et al. Connectivity of diagnostic technologies: improving surveillance and accelerating tuberculosis elimination. Int J Tuberc Lung Dis. 2016;20(8):999–1003. PubMed PMID: 27393530; PubMed Central PMCID: PMCPMC4937753. DOI:10.5588/ijtld.16.0015
  • Denkinger CM, Kik SV, Cirillo D, et al. Defining the needs for next generation assays for tuberculosis. J Infect Dis. 2015;211(S2):S29–S38.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.